Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOGEN INC.

(BIIB)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 10/25 10:07:48 am
267.03 USD   +0.84%
10/22BIOGEN : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BIOGEN INC.
10/22BIOGEN : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/21BIOGEN : UBS Adjusts Price Target on Biogen to $406 From $405, Maintains Buy Rating
MT
10/21BIOGEN : Cowen Adjusts Biogen PT to $375 From $450, Maintains Outperform Rating
MT
10/21BIOGEN : JPMorgan Adjusts Biogen's Price Target to $324 From $425, Maintains Neutral Ratin..
MT
10/21BIOGEN : Morgan Stanley Adjusts Biogen's Price Target to $440 From $447, Maintains Overwei..
MT
10/21BIOGEN : Oppenheimer Adjusts Price Target on Biogen to $390 from $450, Keeps Outperform Ra..
MT
10/21BIOGEN : Needham Adjusts Price Target on Biogen to $386 from $398, Keeps Buy Rating
MT
10/21BIOGEN : RBC Cuts Price Target on Biogen to $295 From $325, Maintains Sector Perform Ratin..
MT
10/21BIOGEN : Reports third quarter 2021 results
AQ
10/21BIOGEN : Wedbush Lowers Price Target on Biogen to $261 From $297, Sees 'More Significant I..
MT
10/20Health Care Up On Defensive Bias -- Health Care Roundup
DJ
10/20S&P 500, Dow near records as earnings reports soothe investor fears
RE
10/20BIOGEN CEO : 'Major bottleneck' still limits Alzheimer's drug
AQ
10/20BIOGEN : Third-Quarter Results Fall as Alzheimer's Drug Sales Miss Street Views; Full-Year..
MT
10/20S&P 500, Dow near record highs on solid forecasts from healthcare firms
RE
10/20BIOGEN : UBS Adjusts Price Target on Biogen to $405 From $442, Maintains Buy Rating
MT
10/20Biogen banks on government coverage to restart stalled Alzheimer's drug sales
RE
10/20WALL STREET STOCK EXCHANGE : Earnings season, bitcoin and the metaverse
10/20BIOGEN : Q3 Non-GAAP Earnings, Revenue Drop; Company Boosts FY Outlook
MT
10/20Biogen Raises Full-Year Guidance
DJ
10/20SAGE THERAPEUTICS : and Biogen Announce Plans to Submit a New Drug Application (NDA) for Z..
AQ
10/20BIOGEN : REPORTS THIRD QUARTER 2021 RESULTS - Form 8-K
PU
10/20BIOGEN : Reports Q3 2021 Earnings
PU
10/20BIOGEN : Q3 2021 Biogen Earnings Presentation
PU
10/20Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
10/20Biogen Inc. Reports Unaudited Impairment Charges for the Three Months Ended September 3..
CI
10/20Biogen Inc. Updates Earnings Guidance for the Full Year of 2021
CI
10/20EARNINGS REACTION HISTORY : Biogen Inc, 33.3% Follow-Through Indicator, 4.8% Sensitive
MT
10/20Biogen 3Q Results Beat Expectations; Alzheimer's Drug Aduhelm Posts Sales of $300,000
DJ
10/19BIOGEN : sales face pressure from slow uptake of Alzhiemer's drug
RE
10/19BIOGEN : Aduhelm Drug for Alzheimer's Remains in Focus Ahead of Q3 Results, Oppenheimer Sa..
MT
10/19SAGE THERAPEUTICS : Biogen Submit Depression Drug Zuranolone New Drug Application to FDA
MT
10/19BIOGEN : Needham Trims Price Target on Biogen to $398 From $400, Maintains Buy Rating
MT
10/19BIOGEN : Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA..
BU
10/19Sage Therapeutics, Inc. and Biogen Inc. Announce Plans to Submit a New Drug Application..
CI
10/19Sage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022
DJ
10/18US Stocks Extend Winning Streak as Factory Output Posts Surprise Drop
MT
10/18CLOSE UPDATE : US Stocks Start Week Mostly Higher Ahead of Next Earnings Batch Even as Fac..
MT
10/18Equities Mixed Midday Following Surprise Dip in Industrial Production
MT
10/18MIDDAY REPORT : US Stocks Mixed Following Surprise Dip in Industrial Production; Treasury ..
MT
10/18Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
DJ
10/18IONIS PHARMACEUTICALS : Partner Biogen Says Tofersen Study Failed to Meet Primary Goal; Sh..
MT
10/18BIOGEN : Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Exte..
AQ
10/18BIOGEN : Tofersen Misses Primary Endpoint But Still Shows Signs of Reduced Disease Progres..
MT
10/17BIOGEN : Announces Topline Results from the Tofersen Phase 3 Studyáand its Open-Label Exte..
AQ
10/17Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Ext..
CI
10/17BIOGEN : trial of ALS drug fails main goal, but company says data are encouraging
RE
10/15BIOGEN : Stifel Adjusts Biogen's Price Target to $344 from $430, Keeps Buy Rating
MT
10/15BIOGEN : Cantor Fitzgerald Adjusts Price Target on Biogen to $327 From $427, Maintains Neu..
MT
10/15Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/15Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/14BIOGEN : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-..
AQ
10/14Biogen Inc. Announces Topline Results from Tofersen Phase 3 Study and Its Open Label Ex..
CI
10/14BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/14BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
10/13BIOGEN : Preliminary Analysis Suggests Certain Multiple Sclerosis Therapies May Reduce COV..
MT
10/13BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/13Biogen Inc. Announces New Data from its Industry-Leading Portfolio of Multiple Sclerosi..
CI
10/13BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
10/13BIOGEN : People Treated With MS Therapies Achieve Antibody Response to Covid-19 Vaccinatio..
DJ
10/12BIOGEN : Morgan Stanley Adjusts Biogen PT to $447 from $455, Keeps Overweight Rating
MT
10/08BIOGEN : Jefferies Adjusts Biogen PT to $400 from $500, Keeps Buy Rating
MT
10/08BIOGEN : Barclays Adjusts Biogen's Price Target to $290 from $395, Keeps Equalweight Ratin..
MT
10/06BIOGEN : to Report Third Quarter 2021 Financial Results October 20, 2021
PU
10/06WALL STREET STOCK EXCHANGE : Less tech, more energy
10/06BIOGEN : RBC Trims Price Target on Biogen to $325 From $326, Maintains Sector Perform Rati..
MT
10/06ANALYST RECOMMENDATIONS : American Airlines, Biogen, Morgan Stanley, Rolls-Royce, United S..
10/05BIOGEN : Wedbush Adjusts Price Target for Biogen to $297 From $314, Maintains Neutral Rati..
MT
10/04Sage Therapeutics and Biogen Announces Consistent Clinically Meaningful Data for Zurano..
CI
09/29BIOGEN : RBC Cuts Price Target on Biogen to $326 From $341, Noting 'Slow Aduhelm Uptake,' ..
MT
09/28BIOGEN : Partner Eisai Launches Rolling Submission of Biologics License Application With F..
MT
09/27BIOGEN : Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Applicat..
PR
09/23BIOGEN : Issues First Progress Report of its Signature Healthy Climate, Healthy Lives&trad..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BIOGEN INC.
01/27/22